Money
FDA Approves Leucovorin for Rare Genetic Disorder, Implications for Treatment Framework
The FDA has approved leucovorin as the first drug for a specific rare genetic disorder, following discussions about its efficacy in autism treatment.
Editorial Staff
1 min read
On March 10, 2026, the FDA granted approval for leucovorin, marking it as the first drug specifically indicated for a rare genetic disorder.
This decision follows extensive discussions regarding the drug's potential efficacy in treating symptoms associated with autism, a topic that has garnered significant attention.
The approval reflects a shift in regulatory focus, as previous claims by the Trump administration had positioned leucovorin as a broader autism treatment option, raising questions about its application in diverse patient populations.